This site is for US healthcare professionals to provide online access to current, accurate, scientific information about our products. It is prepared by Janssen Medical Information and is not intended for promotional purposes, nor for medical advice.

  1. Home
  2. Announcements
  3. Selected Announcement

Neuroscience Conferences

Janssen-sponsored congress materials from select Neuroscience Conferences:

 

Data presented at ACTRIMS 2021

Virtual congress materials from ACTRIMS congress can be accessed directly at https://www.abstractsonline.com/pp8/#!/9245.

Abstracts

 

Data presented at Psych Congress 2020

Virtual congress materials from Psych Congress can be accessed directly at https://www.psychcongress.com/posters.

Posters:

 

Data presented at MSVirtual 2020

Virtual congress materials from MSVirtual congress can be accessed directly at https://library.msvirtual2020.org/virtual-library-search?product_id=7.

Posters

  • Effect of oral ponesimod on clinical disease activity and MRI-based outcomes in patients with relapsing multiple sclerosis: Phase 3 OPTIMUM study – P0071
  • Effect on disability measures and MSFC in patients with relapsing multiple sclerosis from the phase 3 ponesimod versus teriflunomide optimum study – P0204
  • Cardiac Safety of Ponesimod in Relapsing Multiple Sclerosis in the Randomized, Active-Controlled, Double-Blind, Parallel-Group Phase 3 OPTIMUM Study -P0194
  • Establishing Meaningful Change Threshold in Multiple Sclerosis related Fatigue on Fatigue Symptoms & Impacts Questionnaire-Relapsing MS (FSIQ-RMS) – P1027
  • Long-term efficacy and safety of ponesimod: Results from randomized phase II core and extension studies in relapsing remitting multiple sclerosis – P0215
  • Treatment Persistency for Patients in a Phase 2 Long-Term Extension Study of Ponesimod – P0177
  • Pharmacokinetic-Pharmacodynamic Models of Lymphocyte Count and Heart Rate Following Ponesimod Dosing in a Phase 2 Study in Multiple Sclerosis Patients – P0224
  • A real-world study characterizing symptoms and impacts of fatigue in US adults with relapsing multiple sclerosis using a novel disease specific scale – P1004
  • Comorbidity and Economic Burdens of Fatigue Among Patients with Relapsing-Remitting Multiple Sclerosis in the United States – P0857
  • Treatment Preferences of Patients with Relapsing Multiple Sclerosis: A Discrete Choice Experiment – P1064
  • Comparative Efficacy of Relapsing Multiple Sclerosis Therapies: A Model-Based Meta-Analysis for Annual Relapse Rate – P0049
  • Comparative Efficacy of Relapsing Multiple Sclerosis Therapies: A Longitudinal Model-Based Meta-Analysis for Confirmed Disability Accumulation – P0048
  • Quality of life and economic burden of fatigue in people with multiple sclerosis: a systematic literature review – P1048